Objective-Cellular senescence influences organismal aging and increases predisposition to age-related diseases, in particular cardiovascular disease, a leading cause of death and disability worldwide. Peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) is a master regulator of mitochondrial biogenesis and function, oxidative stress, and insulin resistance. Senescence is associated with telomere and mitochondrial dysfunction and oxidative stress, implying a potential causal role of PGC-1α in senescence pathogenesis. Approach and Results-We generated a PGC-1α +/-/apolipoprotein E -/-mouse model and showed that PGC-1α deficiency promotes a vascular senescence phenotype that is associated with increased oxidative stress, mitochondrial abnormalities, and reduced telomerase activity. PGC-1α disruption results in reduced expression of the longevity-related deacetylase sirtuin 1 (SIRT1) and the antioxidant catalase, and increased expression of the senescence marker p53 in aortas. Further, angiotensin II, a major hormonal inducer of vascular senescence, induces prolonged lysine acetylation of PGC-1α and releases the PGC-1α-FoxO1 complex from the SIRT1 promoter, thus reducing SIRT1 expression. The phosphorylation-defective mutant PGC-1α S570A is not acetylated, is constitutively active for forkhead box O1-dependent SIRT1 transcription, and prevents angiotensin II-induced senescence. Acetylation of PGC-1α by angiotensin II interrupts the PGC-1α-forkhead box O1-SIRT1 feed-forward signaling circuit leading to SIRT1 and catalase downregulation and vascular senescence. 
A ge is a major risk factor for many chronic conditions including cardiovascular diseases, such as hypertension and atherosclerosis, which lead to heart failure, myocardial infarction, and stroke. 1 These age-related diseases account for >40% of the mortality in individuals aged ≥65 years in the United States.
1,2 Cellular senescence, a hallmark of organismal aging, is a permanent nonreplicating state characterized by telomere and mitochondrial dysfunction, elevated oxidative stress, 3 and increased expression of senescence-associated β-galactosidase (SA-βG), 4 tumor suppressor protein p53, and cyclin-dependent kinase inhibitors such as p21 (CIP1/WAF1) and p16 (INK4a). 5 Vascular smooth muscle cell (VSMC) senescence in atherosclerotic plaques is a characteristic feature of atherosclerosis, and is associated with increased levels of reactive oxygen species (ROS). 6 Understanding the mechanistic relationships among senescence and age-related disease phenotypes in general is currently a focus of great scientific interest. 7 Angiotensin II (Ang II) is a pluripotent hormone and an important mediator of hypertension and atherosclerosis. 8 Ang II exposure increases ROS production, as well as VSMC senescence and acceleration of atherosclerosis. 9 These effects are mediated importantly by elevated ROS generation through the G-protein-coupled Ang II type 1 receptor (AT 1 R). 10 AT 1 R deficiency in mice extends life span possibly by attenuation of oxidative stress. 11 The molecular mechanisms are incompletely understood.
Peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) enables transcriptional coactivation functions for multiple metabolic and stress response pathways, including carbohydrate and lipid metabolism, oxidative stress resistance, angiogenesis, and mitochondrial biogenesis and function. 12, 13 Regulation of PGC-1α activity is fine-tuned by several interacting posttranslational modifications (including phosphorylation and acetylation) to integrate its multiple physiological functions.
14 Acetylation of PGC-1α by the histone acetyltransferase general control nonderepressible 5 (GCN5) inactivates PGC-1α, whereas deacetylation of PGC-1α by SIRT1 increases its activity. SIRT1 is a negative regulator of senescence. 15 We showed recently that Ang IIstimulated phosphorylation of PGC-1α Ser570 increases the GCN5-mediated acetylation of PGC-1α, leading to reduced catalase expression, increased ROS levels, and hypertrophy in VSMCs. 16 Reduction in catalase expression results in VSMC senescence. 17 Overexpression of human catalase targeted to mitochondria promotes longevity in mice. 18, 19 We found that Ang II decreases catalase expression by releasing forkhead box O1 (FoxO1) from the catalase promoter. 16 Further, we found that FoxO1 binds to 2 cis-acting elements, insulinresponsive sequence 1 (IRS-1) and forkhead-like (FKHD-L), in the SIRT1 promoter, and directly activates SIRT1 transcription through a feed-forward, self-amplifying loop. 20 Collectively, these data imply a potentially important role in the pathogenesis of senescence for PGC-1α, and its posttranslational modification by phosphorylation and acetylation.
Until recently, no specific role had been identified for PGC-1α in modulating the pathogenesis of senescence. Reduced telomerase activity and telomere length are well known to be associated with cellular senescence. 21 Genetically manipulated mice null for telomerase reverse transcriptase exhibited accelerated DNA damage and aging that was associated with mitochondrial dysfunction and reduction in PGC-1α expression. 22 PGC-1α downregulation was mediated by the binding to and blocking of the PGC-1α promoter by the tumor suppressor p53, a mediator of senescence, as noted. A pivotal role of PGC-1α expression in creating the mitochondrial phenotype was established by rescue of compromised mitochondrial function upon PGC-1α transfection. 22 These findings implied a potential role for PGC-1α in senescence and chronic diseases of aging. 23, 24 A causal relationship between cell senescence and organismal aging has been implied also by observations that senescent cells accumulate in aging organs and disrupt structure and function by paracrine or endocrine secretion of substances inducing pathophysiologic responses. 25 Direct evidence was presented recently that senescent cells may harm nonsenescent cells and cause organ dysfunction and disease. 7 The reduction in PGC-1α expression observed in skeletal muscle during aging is consistent with this concept. 26 Furthermore, ectopic expression of PGC-1α in skeletal muscle prevents age-associated muscle wasting in mice. 27 Together, these data provide inferential evidence that the level of PGC-1α expression is an important determinant of cellular senescence, organismal aging, and related chronic diseases. The roles of posttranslational modification and regulation of PGC-1α coactivator function in senescence pathogenesis are largely unknown.
Here, we demonstrate that primary PGC-1α disruption in apolipoprotein E (ApoE) knockout mice (PGC-1α
promotes vascular senescence that is associated with elevated ROS levels, mitochondrial abnormalities, and reduced telomerase activity. Further, PGC-1α deficiency decreases SIRT1 and catalase expression and augments p53 levels in aortas and mouse aortic smooth muscle cells (MASMs). These findings substantiate an important role for PGC-1α in vascular senescence. In primary rat aortic smooth muscle cells (RASMs), Ang II induces prolonged lysine acetylation, suppresses PGC-1α coactivation function, and releases the PGC-1α-FoxO1 complex from the SIRT1 promoter, thus decreasing SIRT1 expression. This downregulation, in turn, enables the sustained acetylation of PGC-1α. Our results provide novel evidence that PGC-1α functions as an important negative regulator of vascular senescence, and provide new insights into the role of PGC-1α posttranslational modifications in the process. Further, the dependency on PGC-1α cotranscriptional activity of the function of the FoxO1-SIRT1 transcriptional control loop informs a novel role for the coactivator in mitigating senescence. These observations substantiate the notion that PGC-1α might be a promising target in the development of interventions for age-related chronic diseases.
Materials and Methods
Materials and Methods are available in the online-only Supplement. To investigate the role of PGC-1α in vascular senescence, we generated PGC-1α -/-and +/-mice in the ApoE -/-background. ApoE is a multifunctional protein that, in addition to its effects on lipoprotein metabolism, has intrinsic activities that enhance inflammation and oxidative stress. 28 The proinflammatory/ prooxidation phenotype of the ApoE knockout enables Ang II-induced senescence in vivo. 6 Similar to PGC-1α -/-homozygotes, 29 PGC-1α -/-/ApoE -/-double knockout mice displayed small size, disordered control of thermogenesis, and increased perinatal mortality. We have, however, successfully nurtured a number of the compound homozygotes into old age (18 months), and used them to inform the role of PGC-1α in vascular senescence. The PGC-1α +/-/ApoE -/-mice, in contrast, showed no visually obvious phenotype and matured normally. Thus, we used these animals to evaluate in detail whether and how PGC-1α deficiency informs development of vascular senescence. Aortas of PGC-1α +/-/ApoE -/-animals exhibited increased SA-βG activity basally ( Figure  1A ; 1.47±0.33-fold), and after Ang II infusion ( Figure 1B Figure 1C and D). Consistent with the known role of PGC-1α in mitigating oxidative stress, we showed that its deficiency in MASMs (PGC-1α +/-/ApoE -/-) was associated with increased ROS levels basally (3.7±0.2-fold compared with control) and after Ang II treatment (4.8±0.2-fold compared with control 2.5±0.3-fold; Figure 1E ).
Results

Primary Disruption of PGC-1α Promotes
PGC-1α plays an important role in mitochondrial biogenesis and function in multiple systems. 14 Mitochondrial dysfunction has been associated frequently with mitochondrial structural abnormalities including mitochondrial fragmentation. 30 We therefore examined the impact of PGC-1α deficiency on mitochondrial structure in MASMs. PGC-1α deficiency promotes accumulation of mitochondrial fragments (Figure 2A ). Average mitochondrial length for PGC-1α wild-type (WT) and deficiency was 2.57 and 2.14 μm, respectively ( Figure  2B ). Moreover, PGC-1α deficiency decreased expression of nuclear respiratory factor-1 and mitochondrial transcription factor A, determinants of mitochondrial biogenesis ( Figure  2C ). As expected, PGC-1α deficiency in MASMs (PGC-1α +/--and PGC-1α
) caused a significant increase in mitochondrial ROS generation, measured by MitoSOX fluorescence intensity (1.9-and 2.4-fold versus control, respectively; Figure III in the online-only Data Supplement). Mitochondria were visualized with MitoTracker Green. Image merging of MitoSOX Red with MitoTracker Green indicates that the enhanced superoxide production by PGC-1α deficiency was generated from mitochondria. Thus, these results are consistent with the notion that primary PGC-1α deficiency impairs mitochondrial structure and increases mitochondrial ROS levels.
Telomere dysfunction, an inducer of senescence, is associated with p53-dependent downregulation of PGC-1α and PGC-1α-dependent genes regulating mitochondrial biogenesis and function. 22 It is unknown, however, whether primary PGC-1α disruption may affect telomere function/activities. We investigated the effect of PGC-1α deficiency on telomerase activity and found that telomerase activity was reduced 85% in MASMs from PGC-1α +/-/ApoE -/-compared with WT mice ( Figure 2D and 2E). Collectively, these data illustrate that PGC-1α gene disruption per se promotes vascular senescence that is associated with elevated oxidative stress, mitochondrial abnormalities, and decreased telomerase activity.
PGC-1α Deficiency Decreases SIRT1 and Catalase Expression and Increases p53 Levels in PGC-1α
To gain mechanistic insights into pathways by which PGC-1α deficiency mediates senescence and oxidative stress, we assessed the effects of this disruption on the expression levels of SIRT1, a negative regulator of senescence, the antioxidant catalase, and the senescence marker p53 in aortas of mice of both genotypes with and without Ang II infusion. The level of PGC-1α expression in the aortas of the heterozygote was decreased by 93% and was not affected significantly by Ang II infusion ( Figure 3A and 3B). The reduction in PGC-1α expression in these mice was associated with a marked decrease in /ApoE -/-mice at 6 to 7 months of age treated without (A) or with angiotensin II (Ang II; B) via osmotic pump were excised for senescence-associated β-galactosidase (SA-βG) staining, as described in Methods. Quantitative analysis of SA-βG staining using fluorescein di-β-D-galactopyranoside (FDG) was performed, as described in Methods. Bar graphs represent relative SA-βG activity. Data (mean±SD; n=14) are expressed as fold change over wild-type. *P<0.05 between the indicated conditions. C through E, Mouse aortic smooth muscle cells (MASMs) isolated from aortas were quiesced and stimulated with or without 100 nmol/L Ang II for 3 days. SA-βG staining (C), quantitative analysis of SA-βG staining using FDG (D), and intracellular ROS levels (E) were determined, as described in Methods, respectively. Scale bar=20 μm. *P<0.05; and **P<0.01 between the indicated conditions. /ApoE -/-mice aortas. Cells were labeled with MitoTracker Orange CMTMRos (A). Average mitochondrial tubule length for wild-type and PGC-1α +/-MASMs was 2.57 and 2.14 μm, respectively (B). *P<0.05. C, PGC-1α deficiency impacts downstream expression networks. PGC-1α downstream targets expression was analyzed by immunoblotting with indicated antibody. D and E, PGC-1α-deficiency decreases telomerase activity in MASMs. D, Amplification products of telomeric repeat were subjected to electrophoresis on a nondenaturing 10% polyacrylamide gel. After ethidium bromide staining, the image was recorded with a charge-coupled device camera imaging system. Lane 7, negative control (minus Taq polymerase); and Lane 8, positive control. E, Telomeric repeat amplification protocol (TRAP) from the same experiment (D) was analyzed for quantification of telomerase activity by measuring fluorescence on a fluorescence plate reader. ***P<0.001. without significant downregulation of PGC-1α expression. These findings led us to posit that the Ang II-induced acetylation and loss of PGC-1α cotranscriptional function that we previously described might be important in inducing senescence. 16 The unanticipated downregulation of SIRT1 could play a pivotal role in this process.
PGC-1α Acetylation Results in Reductions in SIRT1 and Catalase Expression
We showed that Ang II acetylates PGC-1α and downregulates catalase expression in VSMCs in vitro, as noted. 16 Here, we demonstrate that Ang II infusion in vivo is associated with increased serine phosphorylation and lysine acetylation of PGC-1α in the aortas of WT C57BL/6J mice ( Figure 4A and 4B). These modifications of PGC-1α were associated with decreased expression of SIRT1 and catalase and increased p53 expression ( Figure 4C ). There was no change in the expression of PGC-1α. To provide insights and causal relationships among these signaling events, we utilized primary cultures of RASMs. 31 Similar to our observations in aortas, Ang II treatment in RASMs significantly decreased SIRT1 expression over time ( Figure IVA in the online-only Data Supplement), whereas no significant changes were observed in PGC-1α expression ( Figure IVB in the online-only Data Supplement). Taken together, these data suggest that acetylation of PGC-1α by Ang II may link to reduced SIRT1 and catalase expression.
We next determined whether the decrease in SIRT1 expression contributes to the acetylation and inactivation of PGC-1α by Ang II. Prolonged treatment with Ang II in RASMs induces sustained acetylation of PGC-1α ( Figure IVB in the onlineonly Data Supplement), which was decreased by overexpression of WT SIRT1, but not SIRT1-H363Y, a catalytically inactive dominant-negative mutant ( Figure 4D) . Conversely, SIRT1 depletion by small interfering RNA increases basal and Ang II-induced PGC-1α acetylation, which is associated with reduced expression of catalase ( Figure 4E ), and which is dependent on PGC-1α and FoxO1. 16 To evaluate the role of PGC-1α deacetylation by SIRT1 in enabling catalase protein levels, we overexpressed PGC-1α S570A, a phosphorylation-defective mutant that also blocks acetylation. 16 Overexpression of the PGC-1α S570A mutant increases catalase expression and prevents its downregulation by SIRT1 small interfering RNA ( Figure 4F ). Thus, these data indicate that reduction in SIRT1 expression by Ang II leads to elevated and sustained PGC-1α acetylation, which represses PGC-1α cotranscriptional activity and thus results in decreased catalase expression. 
FoxO1 Phosphorylation Is Required for Ang II-Induced SIRT1 Downregulation
We showed recently that FoxO1 directly activates SIRT1 transcription through binding to the IRS-1 and FKHD-like response elements within the SIRT1 promoter. 20 The observation that Ang II reduces SIRT1 expression in vivo and in vitro prompted us to investigate whether inactivation of FoxO1 could mediate Ang II-induced SIRT1 downregulation at the transcriptional level. To test this hypothesis, we conducted 1-step reverse transcription polymerase chain reaction and quantitative real-time PCR in RASMs to determine whether Ang II might impact SIRT1 mRNA abundance. Ang II significantly decreases SIRT1 mRNA after 2 hours of treatment, and the levels were barely detectable by 8 hours ( Figure V in the online-only Data Supplement). We next examined the impact of Ang II on FoxO1 phosphorylation that inhibits FoxO1 transcriptional activity. We found that Ang II (100 nmol/L) stimulates phosphorylation of FoxO1 at both Ser256 and Thr24 sites, which peaks at 5 minutes ( Figure 5A ). We investigated the effect of Ang II on FoxO1 binding to the SIRT1 promoter. Chromatin immunoprecipitation assays using a specific FoxO1 antibody revealed that Ang II stimulation decreases FoxO1 binding to IRS-1 and FKHD-L DNAbinding elements of the SIRT1 promoter in a time-dependent manner ( Figure 5B ). The impaired binding of FoxO1 to the SIRT1 promoter by Ang II was prevented by overexpression of the FoxO1 phosphorylation mutant (TM, S256A/T24A/ S319A; Figure 5C , compare lane 12 with 8), but not FoxO1 WT ( Figure 5C , compare lane 10 with 8). We evaluated the effect of Ang II on FoxO1-dependent SIRT1 transcriptional activities using a luciferase reporter construct containing the 1.5-kb SIRT1 promoter. 20 Ang II stimulation suppresses in a dose-dependent manner FoxO1 (WT)-mediated, but not FoxO1 (TM)-mediated, SIRT1 transcriptional activity. FoxO1 (TM) shows higher SIRT1 promoter activity than FoxO1 (WT; Figure 5D ). Moreover, overexpression of FoxO1 (TM), but not FoxO1 (WT), substantially inhibited Ang II-induced SIRT1 downregulation ( Figure 5E ). Thus, FoxO1 phosphorylation is an early, essential signal for transcriptional downregulation of SIRT1 expression in response to Ang II.
PGC-1α S570A Coactivates FoxO1-Dependent SIRT1 Transcription
PGC-1α coactivates FoxO1-mediated catalase transcription. 16 The observation that PGC-1α disruption in ApoE knockout mice is associated with SIRT1 downregulation prompted us to posit that PGC-1α also regulates FoxO1-dependent SIRT1 transcription. Using reporter transfection assays, we demonstrated that overexpression of the PGC-1α S570A mutant elevates basal and FoxO1-mediated SIRT1 transcriptional activities in RASMs, implying that PGC-1α coactivates SIRT1 transcription through FoxO1 ( Figure  VIA in the online-only Data Supplement). Overexpression of PGC-1α S570A increases SIRT1 protein expression in a dose-dependent manner (Figure VIB in the online-only Data Supplement). To investigate whether FoxO1 is required for PGC-1α-coactivated SIRT1 expression, we examined the effect of FoxO1 depletion using small interfering RNA. Chromatin immunoprecipitation assays showed that endogenous PGC-1α associates with the SIRT1 promoter regions, Figure 5 . FoxO1 phosphorylation is required for longevity-related deacetylase sirtuin 1 (SIRT1) downregulation by angiotensin II (Ang II). A and B, Rat aortic smooth muscle cells (RASMs) were stimulated with 100 nmol/L Ang II for the indicated times. FoxO1 phosphorylation was detected (A). Binding of FoxO1 to SIRT1 promoter was detected by chromatin immunoprecipitation (ChIP) assay (B). C through E, RASMs were infected with Ad.FoxO1 wild-type (WT) or its mutant (TM) or Ad.GFP (as a control) for 24 hours, and treated with Ang II for 4 hours for ChIP assay (C), or stimulated with increasing dose of Ang II for 16 hours for luciferase assay (D) or for 24 hours for SIRT1 expression (E). The relative activity was normalized and calculated as the folds to control or basal group. *P<0.05; and **P<0.01; n=6.
encompassing IRS-1 and FKHD-L elements basally in a FoxO1-dependent manner ( Figure VIC in the online-only Data Supplement). We further determined the impact of FoxO1 depletion on PGC-1α-mediated SIRT1 expression ( Figure  VID in the online-only Data Supplement). Overexpression of the PGC-1α S570A mutant enhanced SIRT1 expression, which was abolished by FoxO1 depletion. FoxO1 small interfering RNA also decreases basal SIRT1 expression, as we previously reported. 20 Association of PGC-1α with FoxO1 in regulation of FoxO1-dependent gene expression in multiple systems is well established. 32, 33 These data suggest that PGC-1α S570A constitutively activates SIRT1 expression, which is mediated by the transcription factor FoxO1. These findings inform a previously unappreciated role for PGC-1α activity in controlling SIRT1 expression.
Inhibition of PGC-1α Acetylation Prevents Ang II-Induced SIRT1 Downregulation
Ang II induces PGC-1α acetylation as well as SIRT1 downregulation. To provide mechanistic understanding into the relationship of these events, we overexpressed the acetylationdefective mutant PGC-1α S570A and determined the effects of Ang II on FoxO1-dependent SIRT1 expression. Chromatin immunoprecipitation assays showed that Ang II stimulation inhibited binding of endogenous PGC-1α ( Figure 6A ), but not of the overexpressed PGC-1α S570A mutant ( Figure 6B ), to the SIRT1 promoter after 2 hours. Similarly, the PGC-1α mutant blocked Ang II-induced release of FoxO1 from the SIRT1 promoter ( Figure 6C ). Moreover, reporter assays indicated that the PGC-1α mutant blocked Ang II-induced reduction of SIRT1 promoter activity ( Figure 6D ). FoxO1 phosphorylation is required for Ang II-induced SIRT1 downregulation ( Figure 5 ). We thus assessed whether PGC-1α S570A inhibits Ang IIstimulated FoxO1 phosphorylation. Overexpression of the PGC-1α mutant blocks basal and Ang II-stimulated FoxO1 phosphorylation at both sites ( Figure 6E ), as well as SIRT1 downregulation by Ang II ( Figure 6F ). Reciprocally, a constitutive-active FoxO1 phosphorylation mutant prevents Ang II-induced PGC-1α acetylation ( Figure VII in the online-only Data Supplement). Thus, the interdependent posttranslational modifications of FoxO1 and PGC-1α modulate feed-forward, self-amplifying SIRT1 transcription.
PGC-1α Is a Negative Regulator of VSMC Senescence
PGC-1α gene deficiency displayed enhanced senescence both in aortas ( Figure 1A and 1B and Figure I in the online-only Data Supplement) and in cultured MASMs ( Figure 1C and  1D ) from ApoE -/-mice. We investigated the role of PGC-1α in Ang II-induced VSMC senescence. We overexpressed PGC-1α S570A in RASMs and determined senescence by SA-βG staining ( Figure 7 and Figure VIII in the onlineonly Data Supplement). Absence of PGC-1α acetylation inhibited Ang II-induced cellular senescence ( Figure 7A) . Similarly, overexpression of the FoxO1 constitutively active form (TM) inhibited Ang II-induced senescence ( Figure 7B ). PGC-1α coactivates FoxO1 to regulate SIRT1 expression. We next asked whether SIRT1 impacts Ang II-induced cellular senescence. Overexpression of SIRT1 WT prevents Ang II-induced senescence ( Figure 7C ). In contrast, depletion of either PGC-1α or FoxO1 or SIRT1 by small interfering RNA significantly enhances basal senescence ( Figure 7D ). These results, together with the previous in vivo observations, demonstrate that PGC-1α functions as a primary negative regulator of VSMC senescence. Together, these data are consistent with the notion that the inactivation of PGC-1α transcriptional coactivation capabilities by acetylation is sufficient to inhibit the FoxO1-SIRT1 signaling axis and enable Ang II-induced cellular senescence ( Figure 7E ). We cannot exclude the possibility that Ang II might target alternative pathways to induce vascular senescence. Thus, in the context of the development of the senescence phenotype, PGC-1α primary gene deficiency and inactivation of its cotranscriptional capability by posttranslational acetylation appear to act similarly in vivo and in vitro.
Discussion
Cellular senescence, a hallmark of organismal aging, is an important risk factor for multiple age-associated diseases, including neurodegenerative, cardiovascular, and metabolic disorders. 34 In particular, senescence has been inferentially implicated in atherosclerotic arterial disease clinically and in animals.
2,35 PGC-1α, an essential regulator of mitochondrial biogenesis and function, is a putative inhibitor of aging-associated systemic conditions, including telomere dysfunction, DNA damage, and elevated oxidative stress. 34 Deregulation of mitochondria with excessive production of ROS is a common unifying feature of diseases and conditions associated with aging. Decreased expression of PGC-1α has been implicated in the onset and progression of age-related neurodegenerative disorders, such as Huntington, Parkinson, and Alzheimer diseases. [36] [37] [38] Overexpression of PGC-1α Drosophila homologue in fruit flies delays aging and prolongs lifespan. 39 The role of PGC-1α in mitigating senescence and the mechanisms involved have been largely unexplored.
Using genetic, transcriptional, molecular, and functional assays, we demonstrate that both PGC-1α deficiency and inactivation of PGC-1α by acetylation induce vascular senescence. Cellular senescence triggered by primary PGC-1α disruption is associated with elevated ROS levels, abnormalities of mitochondrial structure, and reduced telomerase activity coinciding with increased p53 levels and reductions in SIRT1 and catalase expression (Figures 1-3) . Moreover, Ang II-induced acetylation of PGC-1α decreases the binding of the PGC-1α•FoxO1 transcriptional complex to the SIRT1 and catalase promoters and downregulates their expression. Downregulation of SIRT1 expression, in turn, promotes PGC-1α acetylation, which further represses its coactivation ability on FoxO1-mediated SIRT1 and catalase transcription through a feed-forward inhibitory mechanism ( Figure 7E ). Depletion of PGC-1α, FoxO1, or SIRT1 induces senescence, whereas the overexpression of any one of them prevents it (Figure 7) , suggesting that the feed-forward signaling loop among PGC-1α, FoxO1, and SIRT1 is required to prevent senescence. Roles for FoxO1 and SIRT1 in development of senescence have been demonstrated. 40, 41 The findings here provide novel evidence that PGC-1α cotranscriptional activity is also essential in this regard. Taken together, the data provide novel mechanistic understanding of the generally important consequences of PGC-1α downregulation in senescence ( Figure 7E ). 22 PGC-1α cotranscriptional activity is fine-tuned by reversible posttranslational modifications, including phosphorylation and acetylation.
14 Phosphorylation of PGC-1α Ser570 by insulin was identified originally as an inhibitory signal for PGC-1α coactivation of genes involved in gluconeogenesis and fatty acid oxidation. 42 Ser570 phosphorylation of PGC-1α by Ang II triggers enhanced GCN5 recruitment to and lysine acetylation of PGC-1α in vitro 16 and in vivo ( Figure 4 and Figure IX in the online-only Data Supplement). Acetylation of PGC-1α in RASMs releases the PGC-1α-FoxO1 complex from the catalase promoter, thereby inhibiting catalase expression and increasing hypertrophy. 16 We show that the acetylation-defective PGC-1α S570A mutant coactivates FoxO1-dependent SIRT1 expression and prevents Ang IIinduced senescence (Figure 7 and Figure VI in the online-only Data Supplement). In contrast, increased PGC-1α acetylation by SIRT1 downregulation induces senescence ( Figures  4 and 7) . Thus, Ang II enhances PGC-1α acetylation by both increasing its association with GCN5 and by decreasing SIRT1 expression. Moreover, disruption of the PGC-1α gene in mice is associated with reduction in SIRT1 expression (Figure 3) . Reciprocally, the elevated SIRT1 expression levels observed in PGC-1α transgenic mice 27 support the notion that PGC-1α regulates SIRT1 expression.
FoxO1 and SIRT1 are evolutionarily conserved longevity genes involved in a broad spectrum of processes, many of which are salutary for health and development. They act synergistically to modulate aging, oxidative stress, and insulin resistance. 43 We recently showed that FoxO1 directly activates SIRT1 transcription through its association with the DNAbinding elements in the SIRT1 promoter. 20 Ang II treatment stimulates FoxO1 phosphorylation at both Ser256 and Thr24 sites, releases FoxO1 from the SIRT1 promoter, and represses FoxO1 transcriptional activity, thereby decreasing SIRT1 expression ( Figure 5 ). PGC-1α S570A prevents Ang IIinduced SIRT1 downregulation through repression of FoxO1 phosphorylation and chromatin occupancy in the SIRT1 promoter ( Figure 6 ). Reciprocally, a constitutive-active FoxO1 phosphorylation mutant prevents Ang II-induced PGC-1α acetylation ( Figure VII in the online-only Data Supplement). These results indicate that the interdependent posttranslational modifications of FoxO1 and PGC-1α by Ang II are required for the coordinated regulation of SIRT1 expression. Ang II treatment does not alter SIRT1 mRNA half-life (t ½ >8 hours, data not shown), suggesting that Ang II-induced SIRT1 downregulation is not mediated by impaired SIRT1 mRNA stability.
Telomere dysfunction is involved in replicative and stressinduced senescence. 24 Telomere dysfunction upregulates the senescence marker p53 and induces mitochondrial compromise through downregulation of the PGC-1α network. 22 We showed that both PGC-1α deficiency and inactivation by Ang II are associated with upregulation of p53 expression ( Figures  3 and 4) . Thus, vascular senescence may be induced and potentially linked to impaired telomere function by either PGC-1α deficiency or inhibitory posttranslational acetylation in the setting of preserved expression of PGC-1α protein ( Figures  2-4) . Interestingly, we observed that primary PGC-1α deficiency decreases telomerase activity contemporaneously with SIRT1 downregulation (Figures 2 and 3) . SIRT1 deficiency leads to telomere shortening and genomic instability. 44 Increased SIRT1 expression in SIRT1 super mice preserves telomere length, function, and genome stability with aging. Our findings not only broaden understanding of the scope of influence of SIRT1 on aging-related processes, but also embellish the importance of the novel findings that PGC-1α is a major modulator of SIRT1 expression and cellular senescence.
The additive effect of PGC-1α deficiency and Ang II in vascular senescence ( Figure 1B and 1D) suggests that Ang II-induced cell senescence is mediated by PGC-1α/FoxO1/ SIRT1-dependent and independent mechanisms. Consistent with this notion, we observed an additive effect in ROS levels in PGC-1α-deficient cells treated with Ang II (Figure 1E ), suggesting that additional pathways mediated by Ang II could also contribute to development of the senescence phenotype ( Figure 7E ).
PGC-1α plays a pivotal role in improving mitochondrial function and ameliorating oxidative stress via upregulation of genes improving mitochondrial biogenesis, such as mitochondrial transcription factor A and expression of multiple antioxidant enzymes such as catalase. 14, 45 Increased oxidative stress is an important stimulus of cell growth, hypertrophy, and senescence in VSMCs. 46 Overexpression of catalase in mitochondria extends murine life span. 18, 19 We showed previously that PGC-1α acetylation by Ang II downregulates catalase expression, which contributes, at least in part, to elevated ROS levels and VSMC hypertrophy. 16 Here, we demonstrate that PGC-1α deficiency (PGC-1α +/-/ApoE -/-) in MASMs promotes cellular senescence that is associated with mitochondrial structure abnormalities (Figure 2A and 2B) , augmented mitochondrial superoxide production ( Figure III in the online-only Data Supplement), and increased intracellular ROS levels ( Figure 1E ) concomitant with reductions in mitochondrial transcription factor A, nuclear respiratory factor-1, and catalase expression ( Figure 2C ). Furthermore, inactivation of PGC-1α by Ang II-induced acetylation mimics the role of PGC-1α disruption in downregulation of SIRT1 and catalase expression (Figure 3) . Thus, acetylation of PGC-1α appears to be a central regulatory mechanism by which Ang II targets and represses the ROS defense mechanisms to mediate vascular senescence. Our data support the concept that reduced PGC-1α expression and inactivation of PGC-1α by acetylation enable development of cellular senescence, which is associated with elevated oxidative stress and mitochondrial abnormalities.
Recent evidence is consistent with the notion that linkage among oxidative stress, deterioration of telomere function, and mitochondrial dysfunction is mediated by the p53-PGC-1α axis, as noted. Thus, inferentially, PGC-1α likely plays a central role in the pathogenesis of multiple diseases of aging, including atherosclerotic vascular disease. Stein et al 47 reported that PGC-1α disruption does not alter atherogenesis in young PGC-1α 
ApoE
-/-mice on a standard chow diet are more susceptible to age-related atherosclerosis, than are PGC-1α +/+ ApoE -/-mice of similar age, implying a protective role for PGC-1α in the pathogenesis of the disease. An antiaging role of PGC-1α in a lower organism was recently reported. 39 Additional studies are needed that incorporate age as a variable to clarify definitively the role of PGC-1α in atherosclerosis pathogenesis.
In conclusion, we describe novel functions for PGC-1α as a negative regulator of vascular senescence in vivo and in vitro. Oxidative stress and impaired mitochondrial and telomere function/activities are associated in the development of vascular senescence driven by PGC-1α gene deficiency. Deacetylated PGC-1α prevents senescence by enabling FoxO1-dependent SIRT1 transcription. PGC-1α acetylation by Ang II interrupts FoxO1-dependent SIRT1 transcription. This interactive relationship may result in a self-sustaining feedback mechanism perpetuating PGC-1α inactivation ( Figure 7E ). These results provide unique mechanistic insights into the pivotal role for PGC-1α in linking diverse elements of cell senescence induction, including telomere dysfunction, mitochondrial abnormalities, and elevated oxidative stress. Importantly, persistent inhibition of PGC-1α cotranscriptional function by environmentally induced posttranslational modifications such as acetylation, as modeled here, could inform the pathogenesis of cardiovascular and other age-related chronic diseases. The findings should also guide new therapeutic strategies.
